
Revenues of the Cardiovascular and Neuroscience segments increased by 9.3% and 4.3% respectively. Total revenues grew 8.4% year-over-year to $8.6 billion during the three months.
Thierry Piéton, Medtronic’s CEO, said, “Our confidence continues to increase as we advance our revenue growth drivers and execute on efficiencies in manufacturing, supply chain, and operating expenses to drive earnings growth, and increase our growth investments in R&D, sales, and marketing, all with a deliberate focus on creating long-term shareholder value.”
For fiscal 2026, the company continues to expect organic revenue growth of approximately 5%. The guidance for full-year adjusted earnings per share is in the range of $5.60 to $5.66.



